<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H59F1F22AB78347D5BBF6CD87F2AA0DB0" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 796 IH: Second Chance for Moms Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-01-28</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 796</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20250128">January 28, 2025</action-date><action-desc><sponsor name-id="M001211">Mrs. Miller of Illinois</sponsor> (for herself, <cosponsor name-id="B001291">Mr. Babin</cosponsor>, <cosponsor name-id="M001212">Mr. Moore of Alabama</cosponsor>, <cosponsor name-id="M001235">Mr. Moore of West Virginia</cosponsor>, <cosponsor name-id="O000175">Mr. Ogles</cosponsor>, <cosponsor name-id="W000806">Mr. Webster of Florida</cosponsor>, <cosponsor name-id="T000478">Ms. Tenney</cosponsor>, <cosponsor name-id="C001116">Mr. Clyde</cosponsor>, <cosponsor name-id="H001052">Mr. Harris of Maryland</cosponsor>, and <cosponsor name-id="W000814">Mr. Weber of Texas</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Federal Food, Drug, and Cosmetic Act to require a warning label advising that the effects of mifepristone can be counteracted, to amend the Public Health Service Act to establish a hotline to provide information to women seeking to counteract the effects of mifepristone, and for other purposes.</official-title></form><legis-body id="HF5D7DF61033D47849CFE555004B95723" style="OLC"><section id="H939985E47D9E4BABB8F20B2DEC947B5B" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Second Chance for Moms Act</short-title> of 2025</quote>.</text></section><section id="HAA550AF197754B338DE7A2598835F875"><enum>2.</enum><header>Mifepristone warning label and hotline</header><subsection id="HBD43FB87FECC4EF7977EF5F8ADD1C4A2"><enum>(a)</enum><header>Warning label</header><paragraph id="H29FFBADC21D04652A1E7639D20672494"><enum>(1)</enum><header>In general</header><text>Section 502 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/352">21 U.S.C. 352</external-xref>) is amended by adding at the end the following:</text><quoted-block style="traditional" id="H63DA9341809946EE804B0A239817EB36" display-inline="no-display-inline"><subsection id="H9805BE92D939447AA789AE92619582D9"><enum>(hh)</enum><text display-inline="yes-display-inline">If it is the drug mifepristone, and its labeling does not bear the following statement printed in conspicuous text: <quote>WARNING: Medical evidence suggests that the abortifacient effects of mifepristone can be counteracted by natural progesterone, which can increase the chance of fetal survival. The American Society for Reproductive Medicine has determined that natural progesterone is safe in the first trimester of pregnancy. For more information, call [___].</quote> (with the blank filled in to refer to the appropriate number for the hotline under section 1009 of the Public Health Service Act).</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block></paragraph><paragraph id="H05FEB4E178E84354B2CBC236DFA852E6"><enum>(2)</enum><header>Effective date</header><text>Section 502(hh) of the Federal Food, Drug, and Cosmetic Act (as added by paragraph (1)) applies beginning on the date that is 6 months after the date of enactment of this Act.</text></paragraph></subsection><subsection id="HF58F9C4677534FA3991CA844173F2295"><enum>(b)</enum><header>Hotline</header><text display-inline="yes-display-inline">Title X of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300">42 U.S.C. 300 et seq.</external-xref>) is amended by adding at the end the following:</text><quoted-block style="OLC" id="H4EE95A236F45486E982D7598986A825F" display-inline="no-display-inline"><section id="H8141B146B313468B84D73A1D497D35E9"><enum>1009.</enum><header>Hotline for reversal of effects of mifepristone</header><subsection id="H3621C4CCA1E04AA791A79C21188280A0"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary shall establish or maintain, directly or by grant or contract, a toll-free hotline to provide support for 24 hours a day, 7 days a week, for women seeking to reverse the effects of the drug mifepristone.</text></subsection><subsection id="H15C6557BF126413FA904D741E8FC2891"><enum>(b)</enum><header>Referrals to APR providers only</header><text display-inline="yes-display-inline">A referral through the hotline described in subsection (a) may only be made to a health care provider that provides abortion pill reversal services.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section></legis-body></bill> 

